We are live on
!
Find out more
SPA
Sherbrooke Park Advisers Portfolio holdings
AUM
$38.7M
1-Year Est. Return
5.29%
This Fund
S&P 500
This Quarter
Est. Return
+6.29%
1 Year Est. Return
-5.29%
3 Year Est. Return
-9.59%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$230M
AUM Growth
+$15.6M
(+7.3%)
Cap. Flow
+$5.46M
Cap. Flow
% of AUM
2.37%
Top 10 Holdings %
Top 10 Hldgs %
6.97%
Holding
827
New
263
Increased
114
Reduced
126
Closed
324
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$1.45M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$1.42M |
| 3 |
Genpact
G
|
+$1.42M |
| 4 |
C.H. Robinson
CHRW
|
+$1.34M |
| 5 |
OGE Energy
OGE
|
+$1.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$1.44M |
| 2 |
Mondelez International
MDLZ
|
+$1.42M |
| 3 |
Avnet
AVT
|
+$1.21M |
| 4 |
Marvell Technology
MRVL
|
+$1.04M |
| 5 |
XYZ
Block Inc
XYZ
|
+$987K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.25% |
| 2 | Consumer Discretionary | 15.35% |
| 3 | Healthcare | 13.63% |
| 4 | Industrials | 12.99% |
| 5 | Financials | 10.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IAS
426
DELISTED
Integral Ad Science
IAS
| $145K | 0.06% |
17,479
-13,335
| -43% | -$102K |
|
427
DigitalBridge
DBRG
$2.95B
| $144K | 0.06% |
+13,925
| New | +$133K |
|
|
FPI
428
Farmland Partners
FPI
$432M
| $140K | 0.06% |
12,168
-14,612
| -55% | -$157K |
|
429
TFS Financial
TFSL
$4.93B
| $140K | 0.06% |
10,801
-14,619
| -58% | -$188K |
|
|
HBI
430
DELISTED
Hanesbrands
HBI
| $138K | 0.06% |
+30,151
| New | +$145K |
|
431
N-able
NABL
$940M
| $138K | 0.06% |
+16,994
| New | +$127K |
|
432
Vestis
VSTS
$1.88B
| $137K | 0.06% |
+23,979
| New | +$168K |
|
433
Axogen
AXGN
$2.5B
| $133K | 0.06% |
+12,241
| New | +$160K |
|
|
ONTF
434
DELISTED
ON24
ONTF
| $133K | 0.06% |
24,454
-7,162
| -23% | -$36.7K |
|
435
American Express Global Business Travel
GBTG
$4.94B
| $132K | 0.06% |
+20,949
| New | +$135K |
|
436
CorMedix
CRMD
$584M
| $131K | 0.06% |
+10,626
| New | +$117K |
|
437
Novavax
NVAX
$1.31B
| $130K | 0.06% |
20,680
+8,437
| +69% | +$55.9K |
|
438
Ginkgo Bioworks
DNA
$521M
| $127K | 0.06% |
11,318
-6,758
| -37% | -$52.4K |
|
439
WisdomTree
WT
$3.22B
| $126K | 0.05% |
+10,923
| New | +$102K |
|
|
HDSN
440
Hudson Technologies
HDSN
$235M
| $125K | 0.05% |
15,432
-12,864
| -45% | -$88.2K |
|
441
Sally Beauty Holdings
SBH
$1.58B
| $123K | 0.05% |
+13,284
| New | +$114K |
|
|
VISN
442
Vistance Networks Inc
VISN
$2.52B
| $122K | 0.05% |
14,676
+1,431
| +11% | +$7.49K |
|
443
Clarus
CLAR
$143M
| $118K | 0.05% |
34,059
+6,059
| +22% | +$20.5K |
|
444
Granite Ridge Resources
GRNT
$644M
| $116K | 0.05% |
+18,216
| New | +$100K |
|
445
Inogen
INGN
$164M
| $116K | 0.05% |
16,461
-13,363
| -45% | -$89.9K |
|
446
Gray Television
GTN
$552M
| $114K | 0.05% |
25,201
-57,747
| -70% | -$224K |
|
447
Fennec Pharmaceuticals
FENC
$402M
| $114K | 0.05% |
13,742
-4,137
| -23% | -$28.3K |
|
448
Western Union
WU
$2.21B
| $114K | 0.05% |
+13,496
| New | +$128K |
|
449
Xeris Biopharma Holdings
XERS
$1.45B
| $114K | 0.05% |
24,325
+9,448
| +64% | +$43.3K |
|
450
BioCryst Pharmaceuticals
BCRX
$2.4B
| $113K | 0.05% |
+12,658
| New | +$118K |
|
Similar funds
2C
SIM
ISSM
KCM
EFI
ICM
APM
CI
Sherbrooke Park Advisers's Q2 2025 Portfolio in Review
As of Q2 2025, Sherbrooke Park Advisers held 827 positions worth $230M, up 7.3% from $215M the previous quarter. Its ten largest holdings account for 7% of the portfolio.
Sherbrooke Park Advisers's Q2 2025 filing shows 263 new, 114 increased, 126 reduced and 324 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 24,678 shares worth $1.36M. The largest sale was Merck, an estimated $1.44M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Sherbrooke Park Advisers's largest Q2 2025 buy was BioMarin Pharmaceuticals: 24,678 shares worth $1.36M.
- Sherbrooke Park Advisers added most to CMS Energy in Q2 2025, an estimated $1.14M increase.
- Sherbrooke Park Advisers's biggest Q2 2025 reduction was MasTec, cutting an estimated $947K.
- Sherbrooke Park Advisers fully exited Merck in Q2 2025, selling an estimated $1.44M.
- Sherbrooke Park Advisers's ten largest holdings make up 7% of its $230M portfolio in Q2 2025.
- Sherbrooke Park Advisers opened 263 new positions and closed 324 in Q2 2025.
- Sherbrooke Park Advisers's portfolio value rose 7.3% quarter-over-quarter to $230M.
Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.